Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
United Laboratories International Holdings (SEHK:3933) just released phase 2 data for UBT251, a triple agonist for type 2 diabetes, showing larger HbA1c and weight reductions compared with semaglutide and placebo in Chinese patients. See our latest analysis for United Laboratories International Holdings. Despite the strong UBT251 data and recent earnings release, the share price at HK$10.15 reflects a 1 month share price return decline of 21.92% and a 1 year total shareholder return decline...
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mgThe safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical tria
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.